A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated with an ALK inhibitor—but the cancer cells quickly develop resistance to the drug.